Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting
Kim S Thomas(University of Nottingham), Norito Katoh(Kyoto Prefectural University of Medicine), Hidehisa Saeki(Nippon Medical School), L. Howie(National Eczema Association), Laura Howells(University of Nottingham), Louise A. A. Gerbens(Amsterdam UMC Location University of Amsterdam), Maarten Boers(Amsterdam University Medical Centers), T. Ebata(Minamiaoyama Eye Clinic), Laurent Eckert(Sanofi (France)), T. Burton, T. Pawlitschek(Oregon Health & Science University), Joanne R Chalmers(University of Nottingham), Jochen Schmitt(University Hospital Carl Gustav Carus), Phyllis I. Spuls, Christian Apfelbacher(Heidelberg University), Michaela Gabes(University of Regensburg), Beth Stuart(Queen Mary University of London), Eric L. Simpson(Oregon Health & Science University), A. Gadkari(Regeneron (United States)), Erin E. Grinich(Oregon Health & Science University), T. Nakahara(Kyushu University), Hywel C Williams(University of Nottingham)
Cited by 12
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k
The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis..
|British Journal of Dermatology|1994|1.3k